Denosumab Reduces the Incidence of New Vertebral Fractures in Men With Prostate Cancer

被引：3
作者：
David S. Silver
机构：
[1] Cedars Sinai Medical Center/UCLA School of Medicine and the OMC Clinical Research Center,
来源：
Current Osteoporosis Reports | 2010年 / 8卷 / 1期
关键词：
Prostate Cancer; Bone Mineral Density; Lumbar Spine; Bone Loss; Femoral Neck;
D O I：
10.1007/s11914-010-0001-8
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1 / 3
页数：2
相关论文
共 20 条
  • [1] Smith MR(2001)Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer N Engl J Med 345 948-955
  • [2] McGovern FJ(2007)Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer J Clin Oncol 25 1038-1042
  • [3] Zietman AL(2003)Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer J Urol 169 2008-2012
  • [4] Michaelson MD(2007)Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial Ann Intern Med 146 416-424
  • [5] Kaufman DS(2004)Raloxifene to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer: a randomized controlled trial J Clin Endocrinol Metab 89 3841-3846
  • [6] Lee H(2009)Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, and other neoplasms after intravenous bisphosphonates J Clin Oncol 27 1564-1571
  • [7] Smith MR(undefined)undefined undefined undefined undefined-undefined
  • [8] Eastham J(undefined)undefined undefined undefined undefined-undefined
  • [9] Gleason DM(undefined)undefined undefined undefined undefined-undefined
  • [10] Greenspan SL(undefined)undefined undefined undefined undefined-undefined
12